Korean J Otolaryngol-Head Neck Surg.  2002 Mar;45(3):225-230.

The Therapeutic Efficacy of Combined Antiviral Treatment in Sudden Sensorineural Hearing Loss

Affiliations
  • 1Department of Otolaryngology, College of Medicine, Chungbuk National University, Cheongju, Korea. soshin@med.chungbuk.ac.kr

Abstract

BACKGROUND AND OBJECTIVES: The idiopathic sudden sensorineural hearing loss (ISSHL) is a disease occurring instantly or developing over several days. An etiological role for virus families is assumed. Corticosteroids improve the prognosis for hearing recovery in ISSHL, but the effects of acyclovir are still uncertain. The purpose of this study is to evaluate the therapeutic efficacy of antiviral drug acyclovir (Zoylex) in ISSHL.
MATERIALS AND METHODS
One hundred thirty four ears were divided into a study (41 ears, using acyclovir and steroid) and a control (93 ears, using steroid only) groups. Prognostic factors such as initial hearing loss, pattern of initial audiogram, coexistence of dizziness or tinnitus were used for parameters of comparison between two groups.
RESULTS
The overall recovery rate of the study group (53.7%) was better than that of the control group (46.2%), but it was not statistically significant (p>0.05). The recovery rate of the study group was better than that of the control group on some prognostic factors, especially the period between the symptom attack and the beginning of treatment: however, there were no statistically significant differences either (p>0.05).
CONCLUSION
Therefore, no beneficial effects from combining acyclovir with prednisolone could be established in ISSHL.

Keyword

Acyclovir; Deafness; Sudden

MeSH Terms

Acyclovir
Adrenal Cortex Hormones
Deafness
Dizziness
Ear
Hearing
Hearing Loss
Hearing Loss, Sensorineural*
Humans
Prednisolone
Prognosis
Tinnitus
Acyclovir
Adrenal Cortex Hormones
Prednisolone
Full Text Links
  • KJORL-HN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr